2020 Systemic Mastocytosis PIPELINE HIGHLIGHTS Systemic Mastocytosis is one of the widely researched conditions during 2020 with 7 companies actively focusing on realizing pipeline’s potential. Development of Systemic Mastocytosis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Systemic Mastocytosis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Systemic Mastocytosis.
Good progress is anticipated during 2020 and 2021 with Systemic Mastocytosis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Systemic Mastocytosis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Systemic Mastocytosis DRUG DEVELOPMENT PIPELINE OVERVIEW The “Systemic Mastocytosis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Systemic Mastocytosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Systemic Mastocytosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Systemic Mastocytosis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Systemic Mastocytosis DRUG PROFILES
Systemic Mastocytosis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided- • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development • Mechanism of Action • Route of Administration • Companies involved including originator, licensing companies, developer, investors, and others • New molecular entity details • Orphan drug designation and other special status provided by regulators
Systemic Mastocytosis COMPANY PROFILES Both small size and large size pharmaceutical companies are investing their resources in Systemic Mastocytosis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Systemic Mastocytosis. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 7 Systemic Mastocytosis companies including company overview, key snapshot, contact information, and their strategies on accelerating Systemic Mastocytosis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- AB Science SA, Allakos Inc, Arog Pharmaceuticals, Blueprint Medicines Corp, Deciphera Pharmaceuticals , Seattle Genetics Inc, Stemline Therapeutics Inc
Reasons to Buy • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data • Buyers can identify most promising drug candidates for treatment of Systemic Mastocytosis • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations • Users can estimate possible delays in the delivery of pipeline or launch of new products • Stay ahead of competition through understanding their pipeline progression, strategies and outlook • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners
Our reports have been used by over 10K customers, including:
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021 Summary According to the recently published report ’Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021’; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5...
Microbiome - Targeted Therapeutics in Immunology - Thematic Research
The microbiome is considered the genetic material of all microorganisms existing in and on the human body.Large resident microbial communities exist in the gastrointestinal (GI) tract, skin, and respiratory tract, and...
The ePRO, ePatient diaries, and eCOA market in Asia Pacific is expected to grow from US$ 348.8 million in 2021 to US$ 964.2 million by 2028; it is estimated to grow at a CAGR of 15.6% from 2021 to 2028. Healthcare systems are experiencing a rise in consumer engagement worldwide. In developing countries, health care systems are becoming more...
The ePRO, ePatient Diaries, and eCOA market in Europe is expected to grow from US$ 447.8 million in 2021 to US$ 1,184.3 million by 2028; it is estimated to grow at a CAGR of 14.9% from 2021 to 2028. As per the data provided by Clinicaltrials.gov, 2016 has been a big one for clinical research. There were around 366 thousand clinical studies...
The ePRO, ePatient Diaries, and eCOA market in Middle East and Africa is expected to grow from US$ 48.4 million in 2021 to US$ 112.3 million by 2028; it is estimated to grow at a CAGR of 12.8% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. Mobile-enabled...
The ePRO, ePatient Diaries, and eCOA market in South and Central America is expected to grow from US$ 90.3 million in 2021 to US$ 229.0 million by 2028; it is estimated to grow at a CAGR of 14.2% from 2021 to 2028. Patient centricity means designing a treatment, clinical trial, or other health solution centered around the patient. Creating...
The ePRO, epatient diaries, and eCOA market was valued at US$ 1,342.92 million in 2020 and it is projected to reach US$ 4,130.35 million by 2028; it is expected to grow at a CAGR of 15.08% during 2020-2028. Increasing demand for electronic health records (EHRs) and rising use of smartphones are fueling the market growth. However, concerns...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market’s maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs,...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
529 pages •
By Global Industry Analysts
• Apr 2021
- Global Drug Discovery Technologies Market to Reach $74.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at US$44.2 Billion in the year 2020, is projected to reach a revised size of US$74.3 Billion by 2027, growing at aCAGR of 7.7% over the period...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.